Brief: Revive Therapeutics Retains Pharm-Olam To Advance Clinical Study For Bucillamine In Treatment Of Infectious Diseases, Including Covid-19
25/03/2020 21:49
March 25 (Reuters) - Revive Therapeutics Ltd RVV.CD :
* REVIVE THERAPEUTICS - RETAINED PHARM-OLAM, LLC TO ADVANCE
CLINICAL STUDY FOR BUCILLAMINE IN TREATMENT OF INFECTIOUS
DISEASES, INCLUDING COVID-19
Source text for Eikon: ID:nGNX6z9Vm4
Further company coverage: RVV.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Revive Therapeutics
See all newsBrief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Announces Closing Of Second Tranche Of Private Placement
Brief: Revive Therapeutics Nears Completion Of Key Nerve Agent Countermeasure Study With Canadian Department Of National Defence
Brief: Revive Therapeutics Provides Update On Research Study Evaluating Bucillamine For Nerve Agent Exposure